

Primary breast tumor details		
S.No.	Breast cancer type	Grade
1	Invasive breast Carcinoma	2
2	Invasive Breast carcinoma	3
3	Invasive Breast Carcinoma	1
4	Invasive Breast Carcinoma	2
5	Invasive Breast carcinoma	3
6	Ductal Carcinoma In Situ	3
7	Invasive Breast Carcinoma	1
8	Invasive lobular carcinoma	3
9	Invasive Breast carcinoma	2
10	Invasive Breast carcinoma	3
11	Invasive Breast carcinoma	3
12	Invasive Breast carcinoma	3
13	Ductal Carcinoma In Situ	2
14	Residual Invasive Breast Carcinoma	2
15	Invasive Breast carcinoma	2
16	Invasive Breast Carcinoma	2
17	Residual Invasive Breast Carcinoma	3
18	Mucinous Carcinoma	1
19	Invasive Breast carcinoma	2

**Table S1. Tissue microarray patient sample details.** Nineteen breast carcinoma patient samples were included in the the study.

<b>Antibody/Reagent/Kit</b>	<b>Catalog no.</b>	<b>Company</b>
$\alpha$ -tubulin antibody	T5168	Sigma Aldrich, USA
anti-EZH2 antibody	D2C9-5246	Cell Signaling Technology
anti-Rabbit IgG (whole molecule)–Peroxidase antibody produced in goat secondary antibody	A0545	Sigma Aldrich, USA
anti-mouse HRP conjugated secondary antibody	A3682-1ML	Sigma Aldrich, USA
Anti-ERR $\alpha$ antibody	sc-65715	Santacruz Biotechnology
Anti-ERR $\beta$ antibody	sc-376449	Santacruz Biotechnology
Anti-ERR $\gamma$ antibody	sc-393969	Santacruz Biotechnology
SYBER Green	RT-SY2X-03+NRWOU	Eurogentech
SuperScript <sup>®</sup> First-Strand Synthesis System for RT-PCR	11904018	Invitrogen, Carlsbad, CA
Dnase I Kit	AMPD1-1KT	Sigma Aldrich, USA
Lipofectamine 3000		Invitrogen
PVDF membrane	88518, 0.45 $\mu$ m,	Thermo scientific
Skimmed milk	RM1254-500G	Himedia
ECL-HRP for X-ray Film Kit	K-12045-D50	
Trizol	T9424	Sigma Aldrich, USA
MCF-7 cell line	ATCC_HTB-22 <sup>™</sup>	NCCS Pune, Maharashtra, India
T47D cell line	ATCC_HTB-133 <sup>™</sup>	NCCS Pune, Maharashtra, India
MDA-MB-231 cell line	ATCC_HTB-26 <sup>™</sup>	NCCS Pune, Maharashtra, India

**Table S2.** Table provides the details of reagents/cell lines used in the study. All reagents used in the study were obtained from authentic companies.

<b>Primer name</b>	<b>Sequence (5'-&gt;3')</b>
ESRRA SITE 1 F	GTCCCAAATATTGCACGAGATA
ESRRA SITE 1 R	ATCAAACCCCAACCCTCTTTT
ESRRA SITE 2 F	GAAACCCCGTCTCTACTAAAA
ESRRA SITE 2 R	TATCTCGTGCAATATTTGGGAC
ESRRA SITE 3 F	GAAACCCCGTCTCTACTAAAA
ESRRA SITE 3 R	TATCTCGTGCAATATTTGGGAC
ESRRA SITE 4 F	GACTAAGTCTTGCTAATGAGGA
ESRRA SITE 4 R	GACTATTTTGAGAGTGCTTGC
ESRRA SITE 5 F	TAGGTGCTGTAGTGTTATATGC
ESRRA SITE 5 R	GTATTTCAATCACCAGGTCATC
ESRRB SITE 1 F	CTTTGGTTTGGTAGAAGGATAGTAG
ESRRB SITE 1 R	CTATGTGTTAGAAGCAAAGGG
ESRRB SITE 2&3 F	TTGTGGAGCATTTCCTTACA
ESRRB SITE 2&3 R	AAAGGGTTGGGGATCTAAAC
ESRRB SITE 4&5 F	GTTTCTTTCTAGGGCATAAACC
ESRRB SITE 4&5 R	GTTCGATTTTCTCTCTCTTGC
ESRRB SITE 6 F	AGTAGAAATTCAGTGACCACAG
ESRRB SITE 6 R	GGACAAAAGCTATTAGATGCAG
ESRRB SITE 7 F	AAGAGAGGGAAGATACTACCAA
ESRRB SITE 7 R	TCAGAGATCTAGACAAACACAG
ESRRB SITE 8 F	CCAAAGTCACAAGAACTGAAC
ESRRB SITE 8 R	AGAGAAAGAATACCATACCTCG
ESRRB SITE 9 F	CTAGCACTGAATGTAACAAGAC
ESRRB SITE 9 R	CCTGAATATTGTCTCATGGATC
5'Ex1Ezh2	AGAAGGGACCAGTTTGTGG
3'Ex1Ezh2	TTCATCAGCTCGTCTGAACC
GAPDH RT FW	AAGATCATCAGCAATGCCTC
GAPDH RT RV	CTCTTCCTCTTGTGCTCTTG
5'Ex6ERRβF	AAGCCATTGACCAAGATTGT
3'EX7ERRβR	GGTCACAGAGAGTGGTCAGG
5'Ex7ERRαF	CTCAGGGGGTAGGAGAGCAC
3'EX7ERRαR	CTCCCTGGCCAAACCCAAAA
5'Ex2ERRγF	CAGAATGTCAAACAAAGATCGACAC
3'EX3ERRγR	GGTTGAACTGTAGCTCCCACTG

**Table S3.** Table provides the sequence of primers used in the study.






Figure S1: Agarose gel picture of CHIP-qPCR product for positive binding sites of EZH2 on ERR $\alpha$  and ERR $\beta$



**Figure S2: Agarose gel picture of CHIP-qPCR product for negative binding sites of EZH2 on ERRα and ERRβ**



**Figure S3: Immunohistochemistry negative control cases for primary antibodies ERRα, ERRβ, ERRγ and EZH2.**